CCR5 and Hepatic fibrosis: During NASH progression, C-C chemokine receptor type 2 (CCR2) and C-C chemokine receptor type 5 (CCR5), together with their respective ligands, C-C chemokine ligand types 2 (CCL2) and C-C chemokine ligand types 5 (CCL5), promote liver fibrosis by increasing immune cell aggregation and infiltration and amplifying the inflammatory response (167–170).